[HTML][HTML] Update on the etiology, diagnosis and therapeutic management of sexual precocity
Precocious puberty is defined as the development of secondary sexual characteristics
before the age of 8 years in girls and 9 years in boys. Gonadotropin-dependent precocious …
before the age of 8 years in girls and 9 years in boys. Gonadotropin-dependent precocious …
Central precocious puberty: current treatment options
F Antoniazzi, G Zamboni - Pediatric Drugs, 2004 - Springer
Central precocious puberty (CPP) is characterized by early pubertal changes, acceleration
of growth velocity, and rapid bone maturation that often result in reduced adult height. An …
of growth velocity, and rapid bone maturation that often result in reduced adult height. An …
[HTML][HTML] Evaluation of the toxicity of intravitreally injected PLGA microspheres and rods in monkeys and rabbits: effects of depot size on inflammatory response
EA Thackaberry, C Farman, F Zhong… - … & visual science, 2017 - tvst.arvojournals.org
Purpose: Poly (lactic-co-glycolic) acid (PLGA) inserts have been successfully developed for
the treatment of posterior eye disease as a means of reducing injection frequency of …
the treatment of posterior eye disease as a means of reducing injection frequency of …
Regulation and disorders of pubertal timing
BM Nathan, MR Palmert - Endocrinology and Metabolism …, 2005 - endo.theclinics.com
Puberty is a critical human developmental process that leads to sexual maturation and
reproductive capability. It requires an intact hypothalamicpituitary-gonadal (HPG) axis, and …
reproductive capability. It requires an intact hypothalamicpituitary-gonadal (HPG) axis, and …
Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty
PA Lee, K Klein, N Mauras, EK Neely… - The Journal of …, 2012 - academic.oup.com
Context: GnRH agonist (GnRHa) monthly injections are frequently used in the treatment of
central precocious puberty (CPP). The 3-month leuprolide depot 11.25-and 30-mg …
central precocious puberty (CPP). The 3-month leuprolide depot 11.25-and 30-mg …
Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty
JC Carel, J Blumberg, C Seymour… - European journal of …, 2006 - academic.oup.com
Abstract Objective Depot GnRH agonists are commonly used in the treatment of central
precocious puberty (CPP). The triptorelin 11.25 mg 3-month depot, currently used in adult …
precocious puberty (CPP). The triptorelin 11.25 mg 3-month depot, currently used in adult …
60 YEARS OF NEUROENDOCRINOLOGY: MEMOIR: Harris' neuroendocrine revolution: of portal vessels and self-priming
G Fink - Journal of Endocrinology, 2015 - joe.bioscientifica.com
Geoffrey Harris, while still a medical student at Cambridge, was the first researcher (1937) to
provide experimental proof for the then tentative view that the anterior pituitary gland was …
provide experimental proof for the then tentative view that the anterior pituitary gland was …
Treatment of central precocious puberty by GnRH analogs: long‐term outcome in men
S Bertelloni, D Mul - Asian Journal of Andrology, 2008 - Wiley Online Library
In boys, central precocious puberty (CPP) is the appearance of secondary sex
characteristics driven by pituitary gonadotropin secretion before the age of 9 years. In the …
characteristics driven by pituitary gonadotropin secretion before the age of 9 years. In the …
Puberty and its disorders in the male
MR Palmert, YM Chan, L Dunkel - Sperling Pediatric Endocrinology, 2021 - Elsevier
In this chapter we discuss the development of the hypothalamic-pituitary-gonadal (HPG) axis
followed by a description of the physiology of the HPG axis, with a focus on its dynamic …
followed by a description of the physiology of the HPG axis, with a focus on its dynamic …
Current pharmacotherapy of central precocious puberty by GnRH analogs: certainties and uncertainties
S Bertelloni, GI Baroncelli - Expert opinion on pharmacotherapy, 2013 - Taylor & Francis
Introduction: GnRH analogs represent the drug of choice for medical treatment of central
precocious puberty (CPP). They provided prompt and reversible suppression of reproductive …
precocious puberty (CPP). They provided prompt and reversible suppression of reproductive …